Exact Sciences (EXAS) Tops Q2 EPS by 8c, Sales Beat; Raises Cologuard Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Exact Sciences (EXAS) PT Raised to $45 at Canaccord Genuity Following 2Q
July 26, 2017 10:11 AM EDTCanaccord Genuity raised its price target on Exact Sciences (NASDAQ: EXAS) to $45.00 (from $42.00) while maintaining a Buy rating. 2Q revenues of $57.6M came in ahead of the Street's $49.7M. EXAS holds $483M of cash and Cologuard is now covered by 235M... More
